RSS Feed For (NASDAQ:AMED)

AMEDISYS (NASDAQ:AMED)

37.69 +0.21 (0.56%)
AMEDISYS (NASDAQ:AMED) Delayed :
Previous Close $37.48    52 Week High $53.30 
Open $37.49    52 Week Low $25.20 
Day High $37.82    P/E 8.34 
Day Low $36.98    EPS $4.52 
Volume 476,463       
More AMED Info: Chart SEC Filings Profile Historical Options

Amedisys Summary

Amedisys, Inc. provides home health and hospice services in the United States. Its home health services include skilled nursing and home health aide services; physical, occupational, and speech therapy; and medically oriented social work to eligible individuals who require ongoing care.

Links

http://www.amedisys.com

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
EVVV 4 AXE 3
CRDN 3 VLO 3
DB 3 PCAR 3
CNC 3 ETFC 3
MEE 3 WAT 3
ACC 3 CAS 3
View All Friends, Peers and Foes

StreetInsider Reports on AMED by Category

View All Comments Comments on recent AMED articles

ANDREW OLIVER SATCHELL
on Oct 28, 2009
at 05:29 PM
ANDREW OLIVER SATCHELL GOOD
Article: Trading Radar for 10/27: Visa (V), Baidu.com (BIDU), WYNN Resorts (WYNN), RF Micro (RFMD), BP (BP) Report
Anonymous
on Sep 24, 2008
at 11:00 PM
RBC Signals AMED to Outperform Add RBC to Oppenheimer, Wachovia, and BB&T being bullish on Amedisys; see http://www.marketintelligencecenter.com/articles/662272. Who thinks that Andrew Left of Citron is more knowledgeable than all of these RESPECTED players?
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
CRT
on Sep 24, 2008
at 10:36 PM
Tales from the Crypt With the practice of shorting stock indefinitely suspended in the U.S. -- with it possibly becoming illegal under the Bush economic bail out, this may spell the death knell for Citron Research. Shorting stock appears to be a core business strategy employed by the principals of Citron. If what Anonymous said is true about these same principals allegedly shorting Amedisys stock before issuing their "spurious" report, then it must be discounted. Citron may have dug up legitmate dirt on some companies in past, but they also damaged some good ones -- maliciously or not. Bottom line: Take Citron with a grain of salt.
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
Anonymous
on Sep 22, 2008
at 04:23 PM
Here's the 'Secret Sauce' Alluded to in the spurious Citron report... http://www.streetinsider.com/Insiders+Blog/Amedisys+Recognized+among+Top+50+Business+Innovating+Companies+by+InformationWeek+Magazine/4008306.html. Principals at Citron allegedly shorted Amedisys stock before issuing the scathing report. Oppenheimer, Wachovia, and BB&T, et al. weren't fooled. Citron is TOTALLY debunked!
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
Anonymous
on Sep 22, 2008
at 04:18 PM
Here's the Alluded to the the spurious Citron report... http://www.amedisys.com/press_release.cfm?do=view&ID=172. Principals at Citron allegedly shorted Amedisys stock before the scathing report. Oppenheimer, Wachovia, BB&T, et al. weren't fooled. Citron is totally debunked.
Article: Citron Research Raises The Caution Flag On Amedisys (AMED)
View All Comments

Comments on AMED


No comments are currently available.